Sugi Predict

Sugi Predict / Compounds / SCHEMBL19210900

SCHEMBL19210900

SCHEMBL19210900

CC(C)(C)OC(=O)N1C2CCC1CN(c1cc(F)c(Br)cc1F)C2

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ JAK1 P23458 3/20 0.46
▸ CHRM2 P08172 1/20 0.44
▸ CHRM1 P11229 1/20 0.44
▸ CHRM3 P20309 1/20 0.44
▸ HSD11B1 P28845 1/20 0.43
▸ HDAC1 Q13547 1/20 0.41
▸ JAK2 O60674 1/20 0.40
▸ TYK2 P29597 1/20 0.40
▸ JAK3 P52333 1/20 0.40
▸ GPR119 Q8TDV5 3/20 0.40
▸ USP30 Q70CQ3 2/20 0.39
▸ PREP P48147 2/20 0.37
▸ NTRK1 P04629 1/20 0.37
▸ WDR5 P61964 2/20 0.36
▸ KCNK3 O14649 1/20 0.36
▸ KCNK9 Q9NPC2 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ HRH3 Q9Y5N1 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29707393 1.00 JAK1 (0.46) JAK1CHRM2CHRM1CHRM3HSD11B1
SCHEMBL29577318 0.87 JAK1 (0.48) JAK1CHRM2CHRM1CHRM3HSD11B1
SCHEMBL21457817 0.87 JAK1 (0.48) JAK1CHRM2CHRM1CHRM3HSD11B1
SCHEMBL19211100 0.85 JAK1 (0.46) JAK1CHRM2CHRM1CHRM3HSD11B1
SCHEMBL29577102 0.85 JAK1 (0.46) JAK1CHRM2CHRM1CHRM3HSD11B1
SCHEMBL29577303 0.82 JAK1 (0.43) JAK1CHRM2CHRM1CHRM3HSD11B1
SCHEMBL21457824 0.82 JAK1 (0.43) JAK1CHRM2CHRM1CHRM3HSD11B1
SCHEMBL19211003 0.81 MAPT (0.33) USP30
SCHEMBL29707398 0.81 CHRM2 (0.46) JAK1CHRM2CHRM1CHRM3HSD11B1
SCHEMBL19210945 0.80 JAK1 (0.42) JAK1CHRM2CHRM1CHRM3HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12252490-B2 Inhibiting deubiquitinase USP25 and USP28 VALO HEALTH, INC. (US) 2025-03-18 — — US disclosed
EP-3414252-B1 THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS VALO HEALTH INC (US) 2022-07-06 — — EP disclosed
US-11325917-B2 Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2022-05-10 — — US disclosed
CN-109071560-B Thienopyridine carboxamides as ubiquitin-specific protease inhibitors 瓦洛健康公司 2022-01-14 — — CN disclosed
CN-109071561-B Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors 福马治疗股份有限公司 2022-01-14 — — CN disclosed
US-20210179628-A1 INHIBITING DEUBIQUITINASE USP25 AND USP28 VALO HEALTH, INC. 2021-06-17 — — US disclosed
EP-3833441-A1 INHIBITING DEUBIQUITINASE USP25 AND USP28 Valo Early Discovery, Inc. (US) 2021-06-16 — — EP disclosed
CN-112823037-A Inhibition of deubiquitinase USP25 and USP28 瓦洛早期发现股份有限公司 2021-05-18 — — CN disclosed
US-20210047343-A1 THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS VALO HEALTH, INC. 2021-02-18 — — US disclosed
US-10913753-B2 Thienopyridine carboxamides as ubiquitin-specific protease inhibitors VALO EARLY DISCOVERY, INC. (US) 2021-02-09 — — US disclosed
US-10889592-B2 Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors VALO EARLY DISCOVERY, INC. (US) 2021-01-12 — — US disclosed
WO-2020033709-A1 INHIBITING DEUBIQUITINASE USP25 AND USP28 FORMA THERAPEUTICS, INC. (US) 2020-02-13 — — WO disclosed
WO-2020033709-A1 INHIBITING DEUBIQUITINASE USP25 AND USP28 FORMA THERAPEUTICS, INC. (US) 2020-02-13 — — WO disclosed
EP-3414251-B1 THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS FORMA THERAPEUTICS INC (US) 2019-10-16 — — EP disclosed
EP-3414251-A1 THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS Forma Therapeutics, Inc. (US) 2018-12-19 — — EP disclosed
WO-2017139779-A1 THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2017-08-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210047343-A1 THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS USP25, USP28, USP30 JAK1 390/4885CHRM2 4038/4885CHRM1 3445/4885
US-11325917-B2 Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors USP25, USP28, USP30 JAK1 390/4885CHRM2 4038/4885CHRM1 3445/4885
US-10913753-B2 Thienopyridine carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 JAK1 523/4885CHRM2 2648/4885CHRM1 1973/4885
US-10889592-B2 Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors USP25, USP28, USP30 JAK1 390/4885CHRM2 4038/4885CHRM1 3445/4885
US-20210179628-A1 INHIBITING DEUBIQUITINASE USP25 AND USP28 USP28, USP25, USP30 JAK1 872/4885CHRM2 4631/4885CHRM1 4641/4885
US-12252490-B2 Inhibiting deubiquitinase USP25 and USP28 USP28, USP25, USP30 JAK1 872/4885CHRM2 4631/4885CHRM1 4641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.